fda pulls semaglutide restricts non-approved compounded GLP-1 weight loss products FDA Warns on Certain Forms

To help address this knowledge gap, researchers randomized 60 patients undergoing EGD with or without colonoscopy to holding one preprocedure dose of a GLP-1 agonist (hold group) or not holding it (continuation group)

This medication is particularly effective when combined with a healthy diet and regular exercise, enabling patients to lose an average of 2-4 pounds per week

Tirzepatide activates both GLP-1 and GIP receptors, offering a different mechanism that may overcome plateau resistance in certain individuals

Alcohol swab or plain soap-and-water if youre at a sink

You should report any new symptomsunusual anxiety, emotional numbness, return of depressive symptoms, or severe digestive distressto both providers promptly

Although the medications primary mechanism is to regulate blood sugar and suppress appetite, hormonal fluctuations or immune responses induced by the drug may contribute to changes in skin condition